News and Press Releases
ONWARD Medical Announces Publication of One-Year Study Showing Benefit of Sustained Access to ARC-EX Therapy
Study shows significant functional improvements after one year of ARC-EX Therapy Improvements were observed throughout one-year treatment period with no plateau Results demonstrate the importance of sustained access to ARC-EX...
Category: Biotechnology, Clinical Trials, Other
Posted: February 25, 2025
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent with Potential as a Next Generation Checkpoint Inhibitor
11 February 2025 -- London, UK -- Ellipses Pharma Limited, a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced...
Category: BioManufacturing, Drug Discovery, Other, Pharmaceutical
Posted: February 11, 2025
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
23 January 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 23, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
17 December 2024 -- New York, US -- Tiziana Life Sciences, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: December 17, 2024
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
LYT-200 is generally safe and well-tolerated as a single agent as well as in combination with standard-of-care venetoclax and hypomethylating agents LYT-200 demonstrates clinical benefit as a single agent, with...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: December 9, 2024
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers
4 December 2024 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 4, 2024
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
19 September 2024 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: September 19, 2024
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
ArgusEye introduces AugaOne to accelerate downstream bioprocess development
AugaOne sensor system provides specific, real-time and automated data to reduce mAb process development time New sensor will be exhibited at the Bioprocessing Summit, 18-21 March 2024, booth 66. 21...
Category: Biotechnology
Posted: March 21, 2024
